Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 5/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594508 | 0.94 | AGTR1 (0.52) | AGTR1AGTR2 | |
| SCHEMBL9427600 | 0.89 | AGTR1 (0.47) | AGTR1AGTR2 | |
| SCHEMBL4250985 | 0.85 | AGTR1 (0.49) | AGTR1AGTR2 | |
| SCHEMBL9427586 | 0.83 | AGTR1 (0.51) | AGTR1AGTR2 | |
| SCHEMBL594920 | 0.83 | AGTR1 (0.47) | AGTR1AGTR2 | |
| SCHEMBL2073005 | 0.82 | AGTR1 (0.46) | AGTR1AGTR2PPARG | |
| SCHEMBL3630525 | 0.81 | AGTR1 (0.52) | AGTR1AGTR2 | |
| SCHEMBL7009954 | 0.81 | PPARG (0.58) | AGTR1AGTR2PPARG | |
| SCHEMBL650245 | 0.81 | PPARG (0.44) | AGTR1PPARG | |
| SCHEMBL9037151 | 0.81 | AGTR1 (0.47) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5189051-A | Treatment of glaucoma and ocular hypertension with pyrrole angiotensin-II receptor antagonists | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-02-23 | — | — | US | claimed |
| EP-1753746-B1 | NOVEL PYRROLE DERIVATIVES WITH ANGIOTENSIN II ANTAGONIST ACTIVITY | ROTTAPHARM SPA (IT) | 2011-07-27 | — | — | EP | disclosed |
| US-7906501-B2 | Pyrrole derivatives with angiotensin II antagonist activity | ROTTAPHARM S.P.A. (IT) | 2011-03-15 | — | — | US | disclosed |
| US-20070244170-A1 | Novel Pyrrole Derivatives with Angiotensin II Antagonist Activity | ROTTAPHARM BIOTECH S.R.L. (IT) | 2007-10-18 | — | — | US | disclosed |
| US-5189051-A | Treatment of glaucoma and ocular hypertension with pyrrole angiotensin-II receptor antagonists | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244170-A1 | Novel Pyrrole Derivatives with Angiotensin II Antagonist Activity | AGTR2, AGTR1, REN | AGTR1 2/4885AGTR2 1/4885PPARG 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.